jain.com

New compute contracts priced higher since end of June

Company: CoreWeave

Subject kind
customer
Statement date
2026-09-17
Current status
verified

The claim, verbatim

Since the end of June, CoreWeave has been contracting new agreements for compute capacity at higher prices.

Source (primary)

CoreWeave Just Gave Investors Multiple Reasons to Remain Bullish on Its Stock - The Motley Fool (-, news_article)
View cached copy (2026-09-29)Live source ↗Archive.org ↗

Quote: “since the end of June, it has been contracting out new agreements for compute capacity at higher prices”

How we checked this

Checked on October 12, 2026. The cited source supports every part of this claim.

The article reports that on Sept. 17 CoreWeave said that since the end of June it has been contracting new compute capacity agreements at higher prices.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.fool.com/investing/2026/09/28/coreweave-just-gave-investors-multiple-reasons-to-remain-bullish-on-its-stock/) in full (9,091 characters, retrieved September 29, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms CoreWeave Just Gave Investors Multiple Reasons to Remain Bullish on Its Stock - The Motley Fool

Quote: “since the end of June, it has been contracting out new agreements for compute capacity at higher prices”

View cached copy (2026-09-29)Live source ↗Archive.org ↗

confirms CoreWeave Just Gave Investors Multiple Reasons to Remain Bullish on Its Stock - Currently.com

Quote: “since the end of June, it has been contracting out new agreements for compute capacity at higher prices”

View cached copy (2026-09-29)Live source ↗Archive.org ↗

Record of changes

September 29, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 9, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.